

Program	Investigational treatment	Disease	Target patient	Study name	Country/region	Dose finding / safety run-in	Proof of concept	Registration	Approved
Savolitinib MET	Savolitinib + osimertinib (EGFR)	NSCLC	EGFRm/MET+ osimertinib-refractory	SAVANNAH	Global	*			
	Savolitinib + osimertinib (EGFR)	NSCLC	EGFRm/MET+ osimertinib-refractory	SAFFRON	Global	**			
	Savolitinib + durvalumab (PD-1)	Papillary RCC	MET+	SAMETA	Global				
	Savolitinib	NSCLC	MET exon 14 skipping alteration		China				Marketed
	Savolitinib + osimertinib (EGFR)	NSCLC	Treatment-naive, MET+ /EGFRm	SANOVO	China				
	Savolitinib + osimertinib (EGFR)	NSCLC	2L, MET+ /EGFR TKI-refractory	SACHI	China				
	Savolitinib	GC	2L, MET+		China				
Note: HUTCHMED is investigating savolitinib in a global collaboration with AstraZeneca. AstraZeneca leads development outside of China.									
Surufatinib VEGFR-1, -2, -3, FGFR1, CSF-1R	Surufatinib	NET	Advanced metastatic		US				
	Surufatinib	NET	Advanced metastatic		EU				MAA under review
	Surufatinib	NET			JP	(Bridging)			
	Surufatinib + tislelizumab (PD-1)	Solid tumors			US/EU				
	Surufatinib	Pancreatic NET	All	SANET-p	China				Marketed
	Surufatinib	Non-Pancreatic NET	All	SANET-ep	China				Marketed
	Surufatinib + toripalimab (PD-1)	NEC		SURTORI-01	China				
	Surufatinib + toripalimab (PD-1)	ESCC			China				
	Surufatinib + toripalimab (PD-1)	GC, SCLC			China				
	Surufatinib + toripalimab (PD-1)	BTC, sarcoma			China				
Surufatinib + toripalimab (PD-1)	EMC, NSCLC, TC			China					
Fruquintinib VEGFR-1, -2, -3	Fruquintinib	CRC	Refractory	FRESCO-2	US/EU/JP				
	Fruquintinib	BC			US				
	Fruquintinib + tislelizumab (PD-1)	EMC, MSS mCRC, TNBC			US				
	Fruquintinib + tislelizumab (PD-1)	Solid tumors			S Korea				
	Fruquintinib	CRC	≥3L; chemotherapy refractory	FRESCO	China				Marketed
	Fruquintinib + paclitaxel	GC	2L	FRUTIGA	China				
	Fruquintinib + sintilimab (PD-1)	EMC			China				
	Fruquintinib + sintilimab (PD-1)	CRC			China				
	Fruquintinib + sintilimab (PD-1)	HCC, RCC			China				
	Fruquintinib + sintilimab (PD-1)	GI tumors			China				
	Fruquintinib + tislelizumab (PD-1)	Solid tumors			China				
Amdizalisib (HMPL-689) PI3Kδ	Amdizalisib	NHL	Relapsed/refractory		US/EU				
	Amdizalisib	Healthy volunteers			Australia				
	Amdizalisib	FL	Relapsed/refractory		China				
	Amdizalisib	MZL	Relapsed/refractory		China				
	Amdizalisib	HL/NHL	Relapsed/refractory		China				
Sovleplenib (HMPL-523) SYK	Sovleplenib	NHL			Australia				
	Sovleplenib	HL/NHL			US/EU				
	Sovleplenib	ITP	Relapsed/refractory	ESLIM-01	China				
	Sovleplenib	NHL	All		China				
	Sovleplenib	wAHA	All		China	**			
Tazemetostat EZH2	Tazemetostat	ES, FL			China				Marketed (Hainan Pilot Zone)
	Tazemetostat	FL	Relapsed/Refractory	SYMPHONY-1	China	**			
	Tazemetostat	FL	3L		China	** (Bridging)			
Note: Tazemetostat developed by Epizyme. Approved in the US for ES and FL as a monotherapy. HUTCHMED rights are for Greater China – bridging study being planned.									
HMPL-453 FGFR1, 2, 3	HMPL-453	IHCC			China				
	HMPL-453 + Multiple combos	Solid tumors			China				
HMPL-306 IDH 1/2	HMPL-306	Solid tumors	Relapsed/refractory		US/EU				
	HMPL-306	AITL, AML, MDS, MPN	Relapsed/refractory		US/EU				
	HMPL-306	AML, CMML, MDS, MPN	Relapsed/refractory		China				
HMPL-295 ERK, MAPK pathway	HMPL-295	Solid tumors			China				
HMPL-760 BTK	HMPL-760	NHL	Relapsed/refractory		US/EU	**			
	HMPL-760	NHL	Relapsed/refractory		China				
HMPL-653 CSF-1R	HMPL-653	Solid tumors, TGCT			China				



Global



China